PURPOSE: Recent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better understand this topic, we established robust antibody analytics and screened two cohorts of healthy individuals and one cohort of hemophilia patients for the expression of anti-PEG antibodies. METHODS: A flow cytometry approach and a fully validated ELISA platform were established to detect specific anti-PEG antibodies. Immunohistochemistry was used to test for potential binding of anti-PEG antibodies to human tissues. RESULTS: IgM and/or IgG anti-PEG antibodies are expressed by some healthy individuals and by some patients with hemophilia who have not received PEGylated biotherapeutics. These antibodies can be either transient or persistent and recognize PEGs of different sizes with or without terminal methoxy groups. Age and location of healthy individuals influence the prevalence of IgG but not of IgM antibodies. Anti-PEG antibodies do not cross-react with human tissues supporting the safety of the antibodies. CONCLUSION: We confirm that some healthy individuals and some patients with hemophilia express specific antibodies against PEG which are not associated with any pathology and do not bind to human tissues.
PURPOSE: Recent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better understand this topic, we established robust antibody analytics and screened two cohorts of healthy individuals and one cohort of hemophiliapatients for the expression of anti-PEG antibodies. METHODS: A flow cytometry approach and a fully validated ELISA platform were established to detect specific anti-PEG antibodies. Immunohistochemistry was used to test for potential binding of anti-PEG antibodies to human tissues. RESULTS: IgM and/or IgG anti-PEG antibodies are expressed by some healthy individuals and by some patients with hemophilia who have not received PEGylated biotherapeutics. These antibodies can be either transient or persistent and recognize PEGs of different sizes with or without terminal methoxy groups. Age and location of healthy individuals influence the prevalence of IgG but not of IgM antibodies. Anti-PEG antibodies do not cross-react with human tissues supporting the safety of the antibodies. CONCLUSION: We confirm that some healthy individuals and some patients with hemophilia express specific antibodies against PEG which are not associated with any pathology and do not bind to human tissues.
Entities:
Keywords:
PEGylated proteins; anti-PEG antibodies in healthy individuals; anti-PEG antibodies in hemophilia patients; human tissue cross-reactivity study; specificity of anti-PEG antibodies
Authors: E H S Choy; B Hazleman; M Smith; K Moss; L Lisi; D G I Scott; J Patel; M Sopwith; D A Isenberg Journal: Rheumatology (Oxford) Date: 2002-10 Impact factor: 7.580
Authors: Rachel S Lane; F Michael Haller; Anais A E Chavaroche; Andrew Almond; Paul L DeAngelis Journal: Glycobiology Date: 2017-11-01 Impact factor: 4.313
Authors: Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia Journal: Adv Drug Deliv Rev Date: 2021-12-10 Impact factor: 15.470
Authors: Yi Ju; Wen Shi Lee; Emily H Pilkington; Hannah G Kelly; Shiyao Li; Kevin J Selva; Kathleen M Wragg; Kanta Subbarao; Thi H O Nguyen; Louise C Rowntree; Lilith F Allen; Katherine Bond; Deborah A Williamson; Nghia P Truong; Magdalena Plebanski; Katherine Kedzierska; Siddhartha Mahanty; Amy W Chung; Frank Caruso; Adam K Wheatley; Jennifer A Juno; Stephen J Kent Journal: ACS Nano Date: 2022-06-27 Impact factor: 18.027
Authors: Iara Maíra de Oliveira Viana; Sabrina Roussel; Joan Defrêne; Eliana Martins Lima; Frédéric Barabé; Nicolas Bertrand Journal: Acta Pharm Sin B Date: 2021-03-13 Impact factor: 11.413